Skip to main content
2025 CRT Conference Main banner
Back

Robert S. Rosenson, MD

Director of Metabolism and Lipids
Mount Sinai Health System
New York, New York, United States

Robert S. Rosenson, MD, is Professor of Medicine at the Icahn School of Medicine at Mount Sinai and Director of the Metabolism and Lipids Program for the Mount Sinai Health System, New York, New York. He is the recipient of numerous awards and honors, including the Ground-Breaking Doctors Award from Chicago magazine; New York Top Doc from 2015 to 2025; USA Top Doctor in 2019; and recipient of the Simon Dack Award for outstanding scholarship by the Journal of the American College of Cardiology in 2015 - 2017, and 2019 - 2023. He was awarded the Jan J. Kellerman Memorial Award in 2016 by the International Academy of Cardiology for distinguished contributions in the field of cardiovascular disease prevention. In 2019, he was awarded the Clinician Educator Award from the National Lipid Association. He has authored over 460 peer-reviewed articles over 1,000 book chapters, abstracts, and electronic publications.

Disclosure(s): Amgen Inc: Consulting Fees (e.g., advisory boards) (Ongoing); Arrowhead Pharmaceuticals, Inc.: Consulting Fees (e.g., advisory boards) (Ongoing); Avilar Therapeutics: Consulting Fees (e.g., advisory boards) (Ongoing); CRISPR Therapeutics: Consulting Fees (e.g., advisory boards) (Ongoing); Editas Medicine: Consulting Fees (e.g., advisory boards) (Ongoing); Eli Lilly and Company: Consulting Fees (e.g., advisory boards) (Ongoing); GSK: Consulting Fees (e.g., advisory boards) (Ongoing); Intercept Pharmaceuticals Inc: Consulting Fees (e.g., advisory boards) (Ongoing); Kowa American Corporation: Non-promotional lecture (Ongoing); Life Extension: Consulting Fees (e.g., advisory boards) (Ongoing); Lipigon Pharmaceuticals Inc.: Consulting Fees (e.g., advisory boards) (Ongoing); MediMergent LLC: Stock-privately held company (Ongoing); New Amsterdam: Consulting Fees (e.g., advisory boards) (Ongoing); Novartis: Consulting Fees (e.g., advisory boards) (Ongoing); Organon: Consulting Fees (e.g., advisory boards) (Ongoing); Precision BioSciences: Consulting Fees (e.g., advisory boards) (Ongoing); Regeneron Pharmaceuticals Inc.: Consulting Fees (e.g., advisory boards) (Ongoing); Rona Therapeutics, Inc.: Consulting Fees (e.g., advisory boards) (Ongoing); Ultragenyx Pharmaceuticals Inc.: Consulting Fees (e.g., advisory boards) (Ongoing); Verve: Consulting Fees (e.g., advisory boards) (Ongoing); Viatris: Non-promotional lecture (Ongoing); William Blair: Consulting Fees (e.g., advisory boards) (Ongoing); Wolters Kluwer: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing)

Presentation(s):